The efficacy and safety of neoadjuvant chemohormonal therapy followed by robot-assisted radical prostatectomy and/or radiation therapy for prostate cancer patients with oligometastasis: A prospective multicenter study

The efficacy of neoadjuvant chemohormonal therapy followed by robot-assisted radical prostatectomy and/or radiation therapy for prostate cancer patients with oligometastasis: A prospective multicenter study - multimodal therapy for prostate cancer patients with oligometastasis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046528

Enrollment

Registered

2022-02-01

Start date

2020-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Robot-assisted radical prostatectomy Metastasis-Directed radiation therapy Apalutamide Tgafur/Uracil LHRH agonist or antagonist Denosumab

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male patients with prostate cancer (20 years) Bone metastasis within 3 part The patients can intake UFT and apalutamide Performance status 0 or 1

Exclusion criteria

Exclusion criteria: Bone metastasis with 4 part and greater The patients who have multiple lymph node metastases The patients cannot undergo robot-assisted radical prostatectomy due to comorbidities. The patients cannot undergo radiation therapy The patients who received chemotherapy The patients who have osteonecrosis of the jaw

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival, disease-specific survival, efficacy, safety	—

Countries

Japan

Contacts

Public ContactTakuya Koie

Gifu University Urology

goodwin@gifu-u.ac.jp0582306000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026